Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 5/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322769 | 1.00 | SLC1A2 (0.45) | SLC1A2SLC1A3SLC1A1MMEACP3 | |
| SCHEMBL19682745 | 0.86 | SLC1A3 (0.40) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL20889380 | 0.86 | SLC1A3 (0.40) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL20889217 | 0.83 | SLC1A1 (0.38) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL19682369 | 0.83 | SLC1A1 (0.38) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL20889294 | 0.83 | SLC1A3 (0.38) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL19682578 | 0.83 | SLC1A3 (0.38) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL19682746 | 0.82 | SLC1A3 (0.38) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL20889360 | 0.82 | SLC1A3 (0.38) | SLC1A2SLC1A3SLC1A1SLC7A5MEN1 | |
| SCHEMBL20889326 | 0.80 | SLC1A3 (0.37) | SLC1A2SLC1A3SLC1A1MMESLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | SLC1A2 4159/4885SLC1A3 3645/4885SLC1A1 3403/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | SLC1A2 4159/4885SLC1A3 3645/4885SLC1A1 3403/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | SLC1A2 4159/4885SLC1A3 3645/4885SLC1A1 3403/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | SLC1A2 4106/4885SLC1A3 3275/4885SLC1A1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.